Use of MOUNJARO for this indication is supported by a 30-week, randomized, double-blind, placebo-controlled trial with a 22-week open label extension in 99 pediatric patients [see Clinical Studies (14.5)]
In Canada, synthetic injectable peptides are generally regulated as prescription drugs under the Food and Drugs Act, and Health Canada has issued public advisories (April 2026 and earlier) cautioning that unauthorized injectable peptide products are illegal regardless of whether they are labelled 'for research use only.' Research-grade AOD-9604 supplied by Koipeptides is intended for in vitro laboratory study only and is not authorized for any human or veterinary application
A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis
Given the rise in autoimmunity, side effects of multiple medications affecting this pathway and crashing levels of soil cobalt due to glyphosate this why this pathway is wrecked in so many people and why injection are needed by so many and often at high frequency.
Of greater concern are potential risks from combination use: Hypoglycaemia risk: Retatrutide enhances insulin secretion in a glucose-dependent manner, which carries a low intrinsic hypoglycaemia risk when used alone
:max_bytes(150000):strip_icc()/GettyImages-1758233726-9eb529f998844ee8adb39aeb580f0726.jpg)
